|
Neurocognitive Impairments Resulting from Adolescent Prescription Opioid Use Disorder: Longitudinal Impact, Neural Mechanisms, and Comorbidities |
1K99DA056288-01 |
|
NIDA |
2022 |
|
Deep Brain Stimulation (DBS) For Severe Treatment Refractory Methamphetamine Use Disorder |
1UG3DA054746-01A1 |
|
NIDA |
2022 |
|
Effect of buprenorphine on monocytes in the context of neuroAids and opioid abuse |
2R01DA041931-07A1 |
|
NIDA |
2022 |
|
Neural circuitry mediating behavioral flexibility |
3R00DA042934-05S2 |
|
NIDA |
2022 |
|
Methamphetamine Effects on Prefrontal Cortical PV+ Interneurons and Resulting Cognitive Deficits |
3R01DA054589-02S1 |
|
NIDA |
2022 |
|
Facilitating supervised self-management of stimulant medications among adolescents: improving adherence, reducing stigma, and supporting caregivers |
3R43DA053121-01A1S1 |
|
NIDA |
2022 |
|
Role of ARX mutations in marmoset brain organoids |
3U01DA054170-02S1 |
|
NIDA |
2022 |
|
Feasibility of Deep Brain Stimulation as a Novel Treatment for Refractory Opioid Use Disorder |
4UH3DA047714-03 |
|
NIDA |
2022 |
|
Multi-level associations between opioid use and overdose: Individual, clinical, and population-based risk factors for fatality |
5K01DA049950-03 |
|
NIDA |
2022 |
|
Early Stress and the Neurobiology of Susceptibility and Resilience to Substance Use Disorders |
5R01DA017846-13 |
|
NIDA |
2022 |